These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 28838033)

  • 21. Progranulin as a predictive factor of response to chemotherapy in advanced biliary tract carcinoma.
    Kim JH; Do IG; Kim K; Sohn JH; Kim HJ; Jeon WK; Lee SR; Son BH; Shin JH; Nam H; Kwon HJ; Kim MS; Hong HP; Serrero G; Koo DH;
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):1085-1092. PubMed ID: 27744566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis.
    Wang Y; Cheng X; Cui YH; Hou J; Ji Y; Sun YH; Shen ZB; Liu FL; Liu TS
    BMC Cancer; 2018 Jun; 18(1):702. PubMed ID: 29954358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer.
    Cho KM; Park H; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
    Oncotarget; 2017 Jan; 8(2):2329-2341. PubMed ID: 27911876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer.
    Sun D; Ma J; Wang J; Han C; Qian Y; Chen G; Li X; Zhang J; Cui P; Du W; Wu Z; Chen S; Zheng X; Yue Z; Song J; Gao C; Zhao X; Cai S; Hu Y
    Cancer Immunol Immunother; 2019 Sep; 68(9):1527-1535. PubMed ID: 31535160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of care and treatment outcomes in older patients with biliary tract cancer.
    Horgan A; Knox J; Aneja P; Le L; McKeever E; McNamara M
    Oncotarget; 2015 Dec; 6(42):44995-5004. PubMed ID: 26575326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant chemoradiotherapy vs chemotherapy for resectable biliary tract cancer: a propensity score matching analysis based on the SEER database.
    Zhu Y; Liu X; Lin Y; Tang L; Yi X; Xu H; Yuan Y; Chen Y
    Eur J Med Res; 2023 Sep; 28(1):310. PubMed ID: 37658421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.
    Sebbagh S; Roux J; Dreyer C; Neuzillet C; de Gramont A; Orbegoso C; Hentic O; Hammel P; de Gramont A; Raymond E; André T; Chibaudel B; Faivre S
    Acta Oncol; 2016; 55(9-10):1168-1174. PubMed ID: 27333436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer.
    Ulusakarya A; Karaboué A; Ciacio O; Pittau G; Haydar M; Biondani P; Gumus Y; Chebib A; Almohamad W; Innominato PF
    BMC Cancer; 2020 Jun; 20(1):515. PubMed ID: 32493242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases.
    Takahara N; Nakai Y; Isayama H; Sasaki T; Saito K; Oyama H; Kanai S; Suzuki T; Sato T; Hakuta R; Ishigaki K; Takeda T; Saito T; Mizuno S; Kogure H; Tada M; Koike K
    Invest New Drugs; 2018 Dec; 36(6):1093-1102. PubMed ID: 30324343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection.
    Kim YS; Jeong CY; Song HN; Kim TH; Kim HJ; Lee YJ; Hong SC
    Chin J Cancer; 2017 Jan; 36(1):9. PubMed ID: 28086990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer.
    Glimelius B; Hoffman K; Sjödén PO; Jacobsson G; Sellström H; Enander LK; Linné T; Svensson C
    Ann Oncol; 1996 Aug; 7(6):593-600. PubMed ID: 8879373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Main causes of death in advanced biliary tract cancer.
    Kimura-Seto K; Kojima Y; Komori S; Hisada Y; Otake Y; Yanai Y; Saito A; Akazawa N; Tanaka Y; Yokoi C; Yanase M; Akiyama J; Yamamoto N; Yamada K
    Cancer Med; 2023 May; 12(9):10889-10898. PubMed ID: 36991582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
    Woo SM; Lee WJ; Han SS; Park SJ; Kim TH; Koh YH; Kim HB; Hong EK; Park JW; Kim CM
    Chemotherapy; 2012; 58(3):225-32. PubMed ID: 22831988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer.
    Takahara N; Nakai Y; Isayama H; Sasaki T; Saito K; Noguchi K; Suzuki T; Nakamura T; Sato T; Ishigaki K; Hakuta R; Takeda T; Uchino R; Mizuno S; Kogure H; Tada M; Koike K
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1105-1112. PubMed ID: 29038848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4.
    Crosara Teixeira M; Marques DF; Ferrari AC; Alves MF; Alex AK; Sabbaga J; Hoff PM; Riechelmann RP
    Clin Colorectal Cancer; 2015 Mar; 14(1):52-7. PubMed ID: 25442812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy.
    Salati M; Caputo F; Cunningham D; Marcheselli L; Spallanzani A; Rimini M; Gelsomino F; Reggiani-Bonetti L; Andrikou K; Rovinelli F; Smyth E; Baratelli C; Kouvelakis K; Kalaitzaki R; Gillbanks A; Michalarea V; Cascinu S; Braconi C
    Eur J Cancer; 2019 Aug; 117():84-90. PubMed ID: 31276980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy.
    Lamarca A; Rigby C; McNamara MG; Hubner RA; Valle JW
    World J Gastroenterol; 2016 Jul; 22(26):6065-75. PubMed ID: 27468198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer.
    Lim KH; Han SW; Oh DY; Im SA; Kim TY; Bang YJ
    Oncology; 2012; 83(2):57-66. PubMed ID: 22760079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer.
    Thol F; Gairing SJ; Czauderna C; Thomaidis T; Gamstätter T; Huber Y; Vollmar J; Lorenz J; Michel M; Bartsch F; Müller L; Kloeckner R; Galle PR; Wörns MA; Marquardt JU; Moehler M; Weinmann A; Foerster F
    JHEP Rep; 2022 Mar; 4(3):100417. PubMed ID: 35141511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer.
    Goktas Aydin S; Cakan Demirel B; Bilici A; Topcu A; Aykan MB; Kahraman S; Akbıyık I; Atci MM; Olmez OF; Yaren A; Sendur MAN; Geredeli C; Seker M; Urun Y; Karadurmus N; Aydin A
    Curr Med Res Opin; 2022 Oct; 38(10):1751-1758. PubMed ID: 35916475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.